iNtODEWORLD

iNtODEWORLD is the U.S. subsidiary of South Korea-based iNtRON Biotechnology and is used as the group's global-facing vehicle for business development, partnering, and selected R&D activities in bacteriophage-based therapeutics. The company focuses on endolysin and engineered phage technologies for infectious disease, microbiome-linked oncology, and broader immune or immunotherapeutic applications. Its lead clinical asset is SAL200 (Tonabacase), an endolysin-based anti-staphylococcal biologic that has completed Phase 1a, Phase 1b, and Phase 2a studies and has U.S. FDA IND clearance for a Phase 2 program. The broader pipeline includes PHAGERIA for colorectal-cancer-associated microbiome targets and additional phage-derived programs spanning antibacterial, antiviral, and immune-modulating concepts. iNtODEWORLD primarily appears to serve as the U.S. headquarters and partnering arm supporting iNtRON's global commercialization and licensing efforts.